RxDoctor Payments Data

Sorina Macavei, MD

Internal Medicine · Cincinnati, OHNPI 1003800756

Payments from drug & device makers

$1,200in general payments, 2019–2025

Across 69 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$446
  • Novo Nordisk$221
  • Abbott$203
  • Astellas Pharma US Inc$45
  • Novartis$44
  • GSK$32
  • plus $209 from 12 others

What the payments were for

  • Food & beverage$1,200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,200 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$89,548
Medicare patients
311
Services billed
1,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$119,844
OzempicSemaglutide95$112,685
JardianceEmpagliflozin64$86,415
TrulicityDulaglutide50$77,470
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$51,631
FarxigaDapagliflozin Propanediol33$36,687
MounjaroTirzepatide28$31,140
Breo ElliptaFluticasone/Vilanterol22$16,663
Spiriva HandihalerTiotropium Bromide13$15,929
JanuviaSitagliptin Phosphate18$15,641
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$12,749
Advair HfaFluticasone Propion/Salmeterol25$10,433
EntrestoSacubitril/Valsartan12$8,671
Humalog Kwikpen U-200Insulin Lispro13$7,732
MyrbetriqMirabegron11$7,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$119,844104 claims
Novo NordiskOzempic$221$112,68595 claims
Boehringer IngelheimJardiance$12$86,41564 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$32$71,94396 claims
AstraZenecaFarxiga$31$36,68733 claims
NovartisEntresto$44$8,67112 claims
Astellas Pharma US IncMyrbetriq$45$7,69211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →